Zürcher Nachrichten - The quest for a universal coronavirus vaccine

EUR -
AED 3.834856
AFN 72.981026
ALL 98.491871
AMD 410.574545
ANG 1.873597
AOA 958.441534
ARS 1062.068709
AUD 1.668164
AWG 1.879297
AZN 1.774656
BAM 1.956632
BBD 2.099092
BDT 124.232814
BGN 1.958008
BHD 0.392267
BIF 3073.606664
BMD 1.044054
BND 1.4119
BOB 7.184054
BRL 6.348575
BSD 1.039642
BTN 88.383574
BWP 14.369109
BYN 3.402246
BYR 20463.455505
BZD 2.089788
CAD 1.4984
CDF 2996.434335
CHF 0.932371
CLF 0.037427
CLP 1032.725839
CNY 7.619298
CNH 7.624449
COP 4583.396412
CRC 524.522987
CUC 1.044054
CUP 27.667427
CVE 110.312953
CZK 25.108921
DJF 185.128703
DKK 7.458302
DOP 63.306913
DZD 140.708819
EGP 53.090769
ERN 15.660808
ETB 129.594994
FJD 2.419125
FKP 0.826872
GBP 0.82945
GEL 2.934095
GGP 0.826872
GHS 15.282497
GIP 0.826872
GMD 75.171679
GNF 8981.818386
GTQ 8.010405
GYD 217.502466
HKD 8.11186
HNL 26.390219
HRK 7.4889
HTG 136.00782
HUF 413.977438
IDR 16852.07323
ILS 3.801792
IMP 0.826872
INR 88.729074
IQD 1361.878967
IRR 43941.619435
ISK 145.113457
JEP 0.826872
JMD 162.65915
JOD 0.740338
JPY 163.428363
KES 134.213278
KGS 90.832546
KHR 4177.776073
KMF 486.659583
KPW 939.647883
KRW 1514.838471
KWD 0.321516
KYD 0.866368
KZT 545.98211
LAK 22754.673557
LBP 93096.577585
LKR 305.22976
LRD 188.690217
LSL 19.139837
LTL 3.08282
LVL 0.631537
LYD 5.108172
MAD 10.463148
MDL 19.149141
MGA 4905.085269
MKD 61.561171
MMK 3391.046186
MNT 3547.694854
MOP 8.322738
MRU 41.345577
MUR 49.280896
MVR 16.080872
MWK 1802.251891
MXN 20.95141
MYR 4.682524
MZN 66.718935
NAD 19.139837
NGN 1614.576632
NIO 38.256264
NOK 11.798806
NPR 141.414119
NZD 1.845107
OMR 0.401651
PAB 1.039642
PEN 3.871246
PGK 4.215792
PHP 61.207138
PKR 289.37392
PLN 4.260093
PYG 8106.446244
QAR 3.789911
RON 4.977322
RSD 117.017747
RUB 107.411783
RWF 1449.216096
SAR 3.922094
SBD 8.752883
SCR 14.548185
SDG 628.007273
SEK 11.498155
SGD 1.414228
SHP 0.826872
SLE 23.801848
SLL 21893.290418
SOS 594.152588
SRD 36.678625
STD 21609.806806
SVC 9.096867
SYP 2623.21688
SZL 19.135135
THB 35.777638
TJS 11.373235
TMT 3.664629
TND 3.312708
TOP 2.445276
TRY 36.741769
TTD 7.056
TWD 34.125736
TZS 2521.389855
UAH 43.600836
UGX 3813.621262
USD 1.044054
UYU 46.369713
UZS 13403.698233
VES 53.742914
VND 26555.509733
VUV 123.952164
WST 2.884499
XAF 656.235982
XAG 0.035143
XAU 0.000398
XCD 2.821607
XDR 0.793037
XOF 656.235982
XPF 119.331742
YER 261.404956
ZAR 19.098632
ZMK 9397.736499
ZMW 28.771231
ZWL 336.184914
  • CMSD

    0.0000

    23.56

    0%

  • RBGPF

    59.9600

    59.96

    +100%

  • SCS

    -0.5800

    11.74

    -4.94%

  • RIO

    -0.0900

    58.64

    -0.15%

  • AZN

    0.9100

    65.35

    +1.39%

  • RELX

    -0.3100

    45.47

    -0.68%

  • NGG

    0.8200

    58.5

    +1.4%

  • GSK

    0.1700

    33.6

    +0.51%

  • BTI

    0.1131

    36.24

    +0.31%

  • BCC

    -0.2600

    122.75

    -0.21%

  • CMSC

    0.0200

    23.86

    +0.08%

  • BCE

    0.0500

    23.16

    +0.22%

  • VOD

    0.0100

    8.39

    +0.12%

  • JRI

    0.1100

    12.06

    +0.91%

  • RYCEF

    -0.0100

    7.27

    -0.14%

  • BP

    0.1900

    28.6

    +0.66%

The quest for a universal coronavirus vaccine
The quest for a universal coronavirus vaccine / Photo: AHMAD GHARABLI - AFP/File

The quest for a universal coronavirus vaccine

As vaccine makers rush to stamp out new Covid-19 variants, some scientists have set their sights higher, aiming for a universal coronavirus vaccine that could tackle any future strains and possibly even stave off another pandemic.

Text size:

Since the race for a first Covid jab supercharged a new generation of vaccine technology, there have been numerous efforts to develop pan-coronavirus immunisation.

Drew Weissman of the University of Pennsylvania, who was a pioneer of the mRNA technology used in Pfizer's Covid vaccine, is leading one such project.

He said the problem with updating current vaccines to target all existing strains -- a plan announced by Pfizer earlier this month -- is that "new variants are going to appear every three or six months".

After more than two years simply trying to infect more people, he said, the virus is now starting to mutate specifically to get around the immunity gained from vaccines -- much as influenza's constant changing requires an updated shot every year.

"That makes it a little bit trickier, because now you're fighting head-to-head with the virus," Weissman told AFP.

So his team is working on a pan-coronavirus vaccine, which he said has tested well so far.

They are trying to find "highly conserved epitope sequences" -- more integral parts of the virus that cannot mutate readily because it would die without them.

But it's not going to be easy.

"We may have a universal vaccine in two or three years, but we're going to have to keep working on it and changing it over time to keep ahead of the virus," Weissman said.

- Expanding ambitions -

Covid was not the first coronavirus to jump from animals to humans this century: its older relative SARS killed nearly 800 people from 2002-2004, and the Middle East Respiratory Syndrome (MERS) followed in 2012.

When US-based biotech firm VBI Vaccines announced its pan-coronavirus project in the early days of the pandemic in March 2020, it targeted all three.

Francisco Diaz-Mitoma, VBI's chief medical officer, explained the premise by likening each antigen of their proposed vaccine to one of the three primary colours.

The firm hopes to provide antibodies not just for these three -- but also for "the various shades of orange, green, and purple found in between".

"In other words, we are trying to teach the immune system to expand upon the variations of virus it is capable of 'seeing' from the start," he told AFP.

He said VBI's vaccine had shown promising results so far -- including in bats and pangolins -- with clinical studies hoped to start in the coming months ahead of results in early 2023.

The ferritin nanoparticle vaccine effort led by Barton Haynes, director of Duke University's Human Vaccine Institute, has received funding from the US National Institute of Allergies and Infectious Diseases (NIAID).

He told AFP this vaccine, which targets SARS-like viruses but not a broader range of coronaviruses like MERS, had been shown to work well against Omicron.

- 'Leaping one step ahead' -

Pamela Bjorkman of the California Institute of Technology said a true pan-coronavirus vaccine was probably not realistic because there are so many lineages -- some which include common colds.

Her project uses a mosaic nanoparticle approach to target the B lineage of betacoronaviruses, which includes the original SARS-CoV and SARS-CoV-2, the virus that causes the disease Covid.

Bjorkman told AFP that even the "quest" for this specific lineage was comparable to the "many years of effort to make a universal influenza vaccine."

Like Haynes, she said the wide availability of a vaccine depended on how quickly they could begin human trials.

Even if none of the current pan-coronavirus vaccine projects are likely to be rolled out in the next year, their eventual arrival could change the world's relationship with Covid.

"If a pan-coronavirus vaccine is successfully able to establish a broader foundational immunity against coronaviruses, it would allow us, as a global society, to go from being one step behind, to leaping one step ahead of the pandemic," Diaz-Mitoma said.

The broadening horizons of vaccine research could also be one way Covid has forced the world to better prepare for the threat of even worse pandemics ahead.

The US-based Coalition for Epidemic Preparedness Innovations (CEPI) has earmarked $200 million (185 million euros) for pan-coronavirus research.

But it also has a $3.5 billion (3.2 billion euro) plan it hopes will help develop a vaccine targeting "the next Disease X" within 100 days of it emerging -- regardless of whether it is a coronavirus.

J.Hasler--NZN